KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Total Debt (2019 - 2025)

Historic Total Debt for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $489.1 million.

  • GoodRx Holdings' Total Debt fell 45.37% to $489.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.1 million, marking a year-over-year decrease of 45.37%. This contributed to the annual value of $491.7 million for FY2024, which is 2510.0% down from last year.
  • Latest data reveals that GoodRx Holdings reported Total Debt of $489.1 million as of Q3 2025, which was down 45.37% from $490.0 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year Total Debt high stood at $665.9 million for Q1 2021, and its period low was $489.1 million during Q3 2025.
  • For the 5-year period, GoodRx Holdings' Total Debt averaged around $615.0 million, with its median value being $656.8 million (2023).
  • Per our database at Business Quant, GoodRx Holdings' Total Debt tumbled by 35.44% in 2023 and then tumbled by 2510.0% in 2024.
  • GoodRx Holdings' Total Debt (Quarter) stood at $662.9 million in 2021, then dropped by 0.61% to $658.8 million in 2022, then decreased by 0.35% to $656.5 million in 2023, then dropped by 25.1% to $491.7 million in 2024, then decreased by 0.53% to $489.1 million in 2025.
  • Its Total Debt stands at $489.1 million for Q3 2025, versus $490.0 million for Q2 2025 and $490.8 million for Q1 2025.